Mariner
JNCE

Mariner’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Mariner’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-143,218
Closed -$159K – 2913
2022
Q4 		$159K Sell
143,218
-1,185
-0.8% -$1.69K ﹤0.01% 2409
2022
Q3 		$338K Sell
144,403
-172
-0.1% -$609 ﹤0.01% 1690
2022
Q2 		$438K Sell
144,575
-354
-0.2% -$1.72K ﹤0.01% 1171
2022
Q1 		$984K Buy
144,929
+180
+0.1% +$1.28K ﹤0.01% 939
2021
Q4 		$1.21M Sell
144,749
-4,714
-3% -$38.8K 0.01% 780
2021
Q3 		$1.11M Buy
149,463
+8
+0% +$50 0.01% 677
2021
Q2 		$1.02M Buy
149,455
+58
+0% +$482 0.01% 661
2021
Q1 		$1.53M Hold
149,397
– – 0.01% 515
2020
Q4 		$1.05M Hold
149,397
– – 0.01% 552
2020
Q3 		$1.22M Sell
149,397
-31
-0% -$192 0.01% 466
2020
Q2 		$1.03M Buy
149,428
+31
+0% +$167 0.01% 481
2020
Q1 		$710K Buy
+149,397
New +$860K 0.01% 529

Other funds holding JNCE

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Mariner's JNCE Position: Q1 2023 in Review

Mariner sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 143,218 shares — an estimated $159K sold.

Mariner first reported a position in JNCE in Q1 2020 and held it in 12 quarters. The position peaked at $1.53M in Q1 2021. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

  • Mariner reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Mariner sold 143,218 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $159K.
  • Mariner first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
  • Mariner's Jounce Therapeutics, Inc. Common Stock position peaked at $1.53M in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Mariner's 13F filing for Q1 2023, filed 15 May 2023.